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Background: Glufosfamide is a new alkylating agent in which the active metabolite of isophosphoramide
mustard is covalently linked to β-D-glucose to target the glucose transporter system and increase intracellular
uptake in tumor cells. We investigated this drug in a multicenter prospective phase II trial in recurrent glioblas-
toma multiforme (GBM).
Patients and methods: Eligible patients had recurrent GBM following surgery, radiotherapy and no more
than one prior line of chemotherapy. Patients were treated with glufosfamide 5000 mg/m2 administered as a 1-h
intravenous infusion. Treatment success was defined as patients with either an objective response according to
Macdonald’s criteria or 6 months progression-free survival. Toxicity was assessed with the Common Toxicity
Criteria (CTC) version 2.0.
Results: Thirty-one eligible patients were included. Toxicity was modest, the main clinically relevant toxicities
being leukopenia (CTC grade >3 in five patients) and hepatotoxicity (in three patients). No responses were
observed; one patient (3%; 95% confidence interval 0 to 17%) was free from progression at 6 months. Pharmaco-
kinetic analysis showed a 15% decrease in area under the curve and glufosfamide clearance in patients treated
with enzyme-inducing antiepileptic drugs, but no effect of these drugs on maximum concentration and plasma
half-life.
Conclusion: Glufosfamide did not show significant clinical antitumor activity in patients with recurrent GBM.
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Introduction
Despite many trials to improve the outcome of patients with high-
grade glioma, the prognosis of this disease remains dismal. In
particular, the prognosis of glioblastoma is poor, with a median
survival of 9–12 months. Once the tumor recurs following initial
treatment further treatment options are limited. Even chemo-
therapy with temozolomide, recently approved for this indication,
offers a low response rate (5–10%) with ∼20% of patients remaining
free from progression at 6 months after the start of treatment [1, 2].
This shows the clear need for better medical treatment for this
disease, which requires the investigation of new and promising
agents in well-designed phase II trials.
Glufosfamide is a new alkylating agent in which the active
metabolite isophosphoramide mustard is linked to β-D-glucose
[3]. Glufosfamide does not require metabolic activation by
hepatic microsomal enzymes such as the oxazaphosphorines
cyclophosphamide and ifosfamide. There is evidence that the
Na-D-glucose cotransporter SAAT1 mediates the transport of
glufosfamide into human tumor cells and this mechanism may
lead to accumulation of  the drug in tumor cells [3, 4]. Together
with the elevated metabolic rate and glucose consumption rate of
tumor cells, this targeting mechanism probably contributes to the
relative selectivity of glufosfamide for tumor cells. The drug was
found to be active against the glioblastoma multiforme (GBM)
1733
cell line HTB 14 (A. R. Hanauske, Baxter Oncology, data on file).
In phase I studies renal tubular acidosis and neutropenia were the
dose-limiting toxicities. The recommended phase II dose was
4500 mg/m2 when given as a 6-h infusion or 5000 mg/m2 when
given as a 60-min infusion [4, 5]. In phase I studies evidence of
antitumor activity in resistant solid tumors was observed. As part
of a broad phase II program to investigate the activity of glufosfa-
mide in solid tumors, the European Organization for Research and
Treatment of Cancer (EORTC) New Drug Development Group
and Brain Tumor Group investigated this drug in recurrent GBM
(EORTC study 16994G-26002).
Patients and methods
Patients were eligible if they had: a histologically proven GBM at first surgery;
recurrent or progressive disease after radiation therapy; at least one bidimen-
sionally measurable target lesion requiring a contrast enhancing lesion with a
diameter of at least 2 cm on magnetic resonance imaging (MRI) or computed
tomography scan; no more than one line of prior chemotherapy, either given
adjuvant or at first recurrence; no prior high-dose radiotherapy (>65 Gy),
stereotactic radiosurgery or internal radiotherapy; no surgery or radiotherapy
within the last 3 months prior to registration; stable or decreasing dose of steroids
for at least 1 week; adequate hematological, hepatic and cardiac function; normal
renal function as assessed by serum creatinine <150 µmol/l and a creatinine
clearance of ≥60 ml/min as determined by the formula of Cockcroft and Gault;
World Health Organization (WHO) performance status 0–2; age ≥18 years;
given written informed consent. All participating centers obtained approval of
the local medical ethical board prior to study activation.
Before the start of treatment all patients were centrally registered at the
EORTC Data Center in Brussels. The treatment consisted of glufosfamide
5000 mg/m2 administered as a 60-min intravenous infusion every 3 weeks, for
a minimum of 6 months in case of stabilization of the disease or for at least two
cycles after confirmation of an objective response. No nephroprotective
hydration schedule was foreseen in these patients. Response was evaluated
after every two cycles with MRI scanning.
The primary end point of the study was the success rate. A ‘success’ was
defined as either an objective response according to Macdonald’s criteria or
absence of progression for at least 6 months [6, 7]. Secondary end points
included toxicity, the pharmacokinetic profile of glufosfamide, the estimation
of progression-free survival and response duration.
Using the one-step Fleming design, while considering a success rate of <5%
as unacceptable, 28 patients were needed to assure with 90% power and a
type I error of 10% that if the success rate is ≥20% the regimen can be
recommended for further investigation in phase III studies [8]. All analyses
were restricted to patients that started treatment. The success rate and its 95%
confidence interval (CI) were calculated by pooling, in all eligible patients,
those patients with complete response (CR) or partial response (PR) and those
patients with stable disease (SD) for at least 6 months. Progression-free
survival (PFS), overall survival (OS) and duration of response were to be
estimated by the Kaplan–Meier method and calculated from the start of
chemotherapy [9]. OS was measured until the date of death or last follow-up
examination otherwise. PFS was measured until the first sign of radiological or
clinical progression (whichever came first) or death or last follow-up visit
otherwise. Toxicity was assessed according to the Common Toxicity Criteria
(CTC), version 2.0. The relationship of any toxicity was scored as either likely
related to the treatment, unlikely related or relationship not assessable. During
cycle one, blood samples for pharmacokinetic analysis were drawn at 0 h (pre-
dose), at 1 h (immediately post-infusion), at 3 h and at 8 h.
Results
Between February and August 2001, 32 patients were registered
by 12 institutions. Median age was 56 years (range 30–71 years);
the WHO performance status was 0 in five patients, 1 in 22
patients and 2 in five patients. Twenty-five patients had received
prior chemotherapy, following radiotherapy in 17 patients and at
first recurrence in eight patients. One patient was considered
ineligible because the serum bilirubin on the day of entry was >1.5
the upper limit of normal. All patients started treatment. A total of
94 cycles were administered (median two cycles; range 1–8).
Most reported toxicities were considered unrelated to the treat-
ment. In four patients (five cycles) retreatment was delayed,
which was due to neutropenia (CTC grade 2) in three patients. The
relative dose intensity of glufosfamide was between 90% and
110% of the theoretical dose for all patients but one. Grade 3 or 4
hematological toxicity (leukopenia or neutropenia) was observed
in six patients (16 cycles). Three patients developed a grade 3
hepatotoxicity, with a predominant increase of alanine amino-
transferase and γ-glutamyltransferase. The ineligible patient with
a baseline increase in bilirubin (CTC grade 2) developed a grade 3
increase in bilirubin, with full recovery after discontinuation of
treatment. One other patient developed a grade 2 creatinine
increase with a grade 2 proteinuria. One patient developed a grade
3 infection and one patient grade 3 vomiting. Several grade 3
electrolyte disturbances were observed (hyponatremia, hypo- and
hypercalemia, hypermagnesemia, hypophosphatemia) and one
grade 4 hypocalemia.
At the time of this report, all but one patient have progressed and
17 patients have died. No responses were observed, 10 patients had
no change after two cycles and one patient (3%; 95% CI 0 to 17%)
remained free from progression at 6 months.
Four patients were excluded from the pharmacokinetic analysis,
because they had erroneously received a nephroprotective hydration
schedule which may influence pharmacokinetic parameters. A
moderate inter-individual variability was observed in the remaining
27 patients. Table 1 shows pharmacokinetic parameters for all
non-hydrated patients. Patients treated with enzyme-inducing
antiepileptic drugs (EIAED; carbamazepine, phenytoine, pheno-
barbital, oxcarbazepine) showed a statistically significant
decrease of ∼15% of the glufosfamide clearance and the area
under the curve (AUC; P = 0.043) as compared with patients not
using these agents. No significant differences were observed in
glufosfamide maximum concentration and plasma half-life time.
Discussion
Glufosfamide showed a low hematological and non-hematological
toxicity profile in GBM patients. The relatively large volume that
was administrated in a short time (1000 ml in 60 min) did not
cause increased edema or neurological deterioration during or
shortly after the infusion, events that have been observed in brain
tumor patients receiving hydration before cisplatin [10]. The pre-
dominant toxicity consisted of neutropenia and hepatotoxicity. In
one patient a grade 2 renal toxicity was observed. Glufosfamide
was well tolerated in this group of patients. No objective
responses were observed, and only one of 31 patients (3%; 95%
1734
CI 0 to 17%) remained free from progression at 6 months after the
start of treatment. The pharmacokinetic analysis in this study
showed overall a profile comparable to results obtained in phase I
and II studies in patients with non-neurological solid tumors (data
not shown). In the group of patients treated with EIAED, a slight
(15%) increase in clearance and AUC was observed. Glufosfamide
is not metabolized through interaction with CYP3A4 cytochrome
and beforehand no interaction was expected. The differences are
small however, especially in view of the more pronounced and
clinically relevant interactions observed with paclitaxel and CPT-11
[11, 12]. Whether the presently observed interaction is of clinical
relevance remains to be established. Its shows, however, the rele-
vance of pharmacokinetic studies in studies on medical treatment
of brain tumors, even if beforehand no interaction is expected.
In studies on primary brain tumors, Macdonald’s criteria have
been widely accepted as the primary end point [6]. Several recent
trials on GBM used the percentage of patients remaining free from
progression at 6 months as the primary end point, using a large
database with negative phase II trials on GBM as a reference
source [1, 2]. The advantage of the latter criterion is that it
acknowledges the clinical benefit of SD for a patient with a
disease in which a rapidly progressive course is the rule [7, 13].
The use of this criterion also allows comparison to future trials
with new agents in which a true response is not to be expected. We
felt reluctant to leave out the objective response criterion (partial
or complete response) because true responses (partial or com-
plete), regardless of duration, would still imply clinical activity of
glufosfamide. We therefore combined both end points and con-
sidered as a treatment ‘success’ any patient in which either a partial
or complete response was observed, or in which 6 months PFS
was obtained. Unfortunately, only one patient in the present study
met these conditions.
In conclusion, treatment with glufosfamide was in general well
tolerated but did not show significant activity in GBM. The
present study does not support further investigations of glufosfamide
in recurrent GBM.
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Table 1. Results of pharmacokinetic analysis in the 27 non-hydrated patients: mean values (ranges)
aSamples from 27 patients included.
bSamples from 17 patients included.
AUC, area under the curve; Cmax, maximum concentration; EIAED, enzyme-inducing antiepileptic drugs; P value, difference between 
patients with and without EIAED; t½, terminal half-life.
No. of 
patients
Cmax (µg/ml) t½ (h) AUC (µg·h/ml) Clearance 
(ml/min/m2)
All patients 26 479 (382–696)a 1.8 (1.3–2.9) 1487 (1086–2204) 57 (38–77)
With EIAED 10 451 (384–500) 1.7 (1.4–2.2) 1341 (1086–1669) 62 (48–77)
Without EIAED 16 495 (382–696)b 1.9 (1.3–2.9) 1579 (1114–2204) 54 (38–71)
P value 0.145 0.206 0.043 0.043
